Hepatobiliary Cancer

  • Jennifer S. ChangEmail author
  • Mekhail Anwar


This chapter will discuss the diagnosis, workup, and management of hepatocellular carcinoma, gallbladder cancer, and intrahepatic and extrahepatic cholangiocarcinoma.


Hepatocellular carcinoma (HCC) Gallbladder cancer Cholangiocarcinoma 



We thank Chien Peter Chen MD, Kim Huang MD, and Mack Roach III MD, for their work on the prior edition of this chapter.


  1. Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of Unresectable intrahepatic cholangiocarcinoma with yttrium-90 Radioembolization: a Systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120–7.CrossRefGoogle Scholar
  2. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys. 1994;28:945–51.CrossRefGoogle Scholar
  3. Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):772.CrossRefGoogle Scholar
  4. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.CrossRefGoogle Scholar
  5. Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15:3147–56.CrossRefGoogle Scholar
  6. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–9.CrossRefGoogle Scholar
  7. Crane CH, MacDonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53:969–74.CrossRefGoogle Scholar
  8. Cubertafond P, Mathonnet M, Gainant A, et al. Radical surgery for gallbladder cancer. Results of the French surgical association survey. Hepatogastroenterology. 1999;46:1567–71.PubMedGoogle Scholar
  9. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–8.CrossRefGoogle Scholar
  10. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.CrossRefGoogle Scholar
  11. Engineer R, Goel M, Chopra S, et al. Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers : a new paradigm. Ann Surg Onc. 2016;23(9):3009–15.CrossRefGoogle Scholar
  12. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.CrossRefGoogle Scholar
  13. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2015;1(6):756–65.CrossRefGoogle Scholar
  14. Kim Y, Amini N, Wilson A, et al. Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer : a multi-institutional analysis. Ann Surg Onc. 2016;23(9):2998–3008.CrossRefGoogle Scholar
  15. Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotacti body radiation therapy. Pract Radiat Oncol. 2015;5(5):e443–9.CrossRefGoogle Scholar
  16. Mantripragada KC, Hamid F, Shafgat H, Olszewski AJ. Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base. J Natl Cancer Inst. 2016;109(2):pii. djw202Google Scholar
  17. McPartlin AJ, Dawson LA. Stereotactic body radiotherapy for hepatocellular carcinoma. Cancer J. 2016;22(4):296–301.CrossRefGoogle Scholar
  18. Mornex F, Girarda N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies – mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66:1152–8.CrossRefGoogle Scholar
  19. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers. Available at: Accessed on 25 Jan 2017.
  20. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73:148–53.CrossRefGoogle Scholar
  21. Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3):S94–S100.CrossRefGoogle Scholar
  22. Pollom EL, Alagappan M, Park LS, et al. Does radiotherapy still have a role in Unresected biliary tract cancer? Cancer Med. 2016. Scholar
  23. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53(3):399–404.CrossRefGoogle Scholar
  24. Seong J, Shim SJ, Lee IJ, et al. Evaluation of the prognostic value of Okuda, cancer of the liver Italian program, and Japan integrated staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1037–42.CrossRefGoogle Scholar
  25. Schoenthaler R, Phillips TL, Efrid JT, et al. Carcinoma of the extrahepatic bile ducts, the University of California at San Francisco experience. Ann Surg. 1994;219:267–74.CrossRefGoogle Scholar
  26. Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2015;34(3):219–26.CrossRefGoogle Scholar
  27. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized Stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657–64.CrossRefGoogle Scholar
  28. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:581–7.CrossRefGoogle Scholar
  29. Valle JW, Hasan HS, Palmer DD, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRefGoogle Scholar
  30. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–9.CrossRefGoogle Scholar
  31. Wang SJ, Fuller CD, Kim JS, et al. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 2008;26:2116–7.Google Scholar
  32. Wang Y, Li J, Xia Y, et al. Prognostic Nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.CrossRefGoogle Scholar
  33. Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10:307–16.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation Oncology, University of California San FranciscoMarin General HospitalSan FranciscoUSA
  2. 2.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations